Multivariate analysis for cytogenetics and clinical and biologic variables (all patients)
. | All patients within study . | . | . | . | Patients 60 y or younger . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | OS . | . | DFS . | . | OS . | . | DFS . | . | ||||||
. | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | ||||||
| Age, 60 y or younger vs older than 60 y | < .001 | 1.90 (1.65-2.15) | < .001 | 1.91 (1.50-2.42) | — | — | — | — | ||||||
| Cytogenetics*† | ||||||||||||||
| Low | < .001 | 0.48 (0.33-0.69) | .002 | 0.48 (0.30-0.77) | .005 | 0.55 (0.36-0.84) | .039 | 0.56 (0.32-0.97) | ||||||
| High | < .001 | 1.86 (1.57-2.2) | < .001 | 2.08 (1.51-2.87) | < .001 | 1.80 (1.42-2.80) | .001 | 1.98 (1.35-2.91) | ||||||
| WBC count† | ||||||||||||||
| Intermediate (> 9.2 ≤ 21.7 GPT/L) | < .005 | 1.30 (1.08-1.55) | .024 | 1.43 (1.05-1.96) | .082 | 1.26 (0.97-1.64) | NS | — | ||||||
| Highest, 21.7 or more GPT/L | < .001 | 1.48 (1.25-1.75) | < .001 | 1.88 (1.41-2.51) | .002 | 1.48 (1.16-1.89) | .005 | 1.69 (1.17-2.44) | ||||||
| De novo AML vs sAML | .001 | 0.73 (0.58-0.91) | .013 | 0.63 (0.44-0.91) | .002 | 0.65 (0.49-0.85) | .041 | 0.60 (0.36-0.98) | ||||||
| NPM1-FLT3 group | ||||||||||||||
| NPM1-mut/FLT3-ITDneg | .005 | 0.73 (0.58-0.91) | .086 | 0.75 (0.54-1.042) | .037 | 0.71 (0.51-0.98) | .082 | 0.67 (0.43-1.05) | ||||||
| NPM1-mut/FLT3-ITDpos | NS | — | NS | — | .089 | 1.33 (0.96-1.87) | NS | — | ||||||
| NPM1-wt/FLT3-ITDpos | NS | — | < .001 | 1.97 (1.38-2.82) | NS | — | .014 | 1.70 (1.12-2.59) | ||||||
. | All patients within study . | . | . | . | Patients 60 y or younger . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | OS . | . | DFS . | . | OS . | . | DFS . | . | ||||||
. | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | ||||||
| Age, 60 y or younger vs older than 60 y | < .001 | 1.90 (1.65-2.15) | < .001 | 1.91 (1.50-2.42) | — | — | — | — | ||||||
| Cytogenetics*† | ||||||||||||||
| Low | < .001 | 0.48 (0.33-0.69) | .002 | 0.48 (0.30-0.77) | .005 | 0.55 (0.36-0.84) | .039 | 0.56 (0.32-0.97) | ||||||
| High | < .001 | 1.86 (1.57-2.2) | < .001 | 2.08 (1.51-2.87) | < .001 | 1.80 (1.42-2.80) | .001 | 1.98 (1.35-2.91) | ||||||
| WBC count† | ||||||||||||||
| Intermediate (> 9.2 ≤ 21.7 GPT/L) | < .005 | 1.30 (1.08-1.55) | .024 | 1.43 (1.05-1.96) | .082 | 1.26 (0.97-1.64) | NS | — | ||||||
| Highest, 21.7 or more GPT/L | < .001 | 1.48 (1.25-1.75) | < .001 | 1.88 (1.41-2.51) | .002 | 1.48 (1.16-1.89) | .005 | 1.69 (1.17-2.44) | ||||||
| De novo AML vs sAML | .001 | 0.73 (0.58-0.91) | .013 | 0.63 (0.44-0.91) | .002 | 0.65 (0.49-0.85) | .041 | 0.60 (0.36-0.98) | ||||||
| NPM1-FLT3 group | ||||||||||||||
| NPM1-mut/FLT3-ITDneg | .005 | 0.73 (0.58-0.91) | .086 | 0.75 (0.54-1.042) | .037 | 0.71 (0.51-0.98) | .082 | 0.67 (0.43-1.05) | ||||||
| NPM1-mut/FLT3-ITDpos | NS | — | NS | — | .089 | 1.33 (0.96-1.87) | NS | — | ||||||
| NPM1-wt/FLT3-ITDpos | NS | — | < .001 | 1.97 (1.38-2.82) | NS | — | .014 | 1.70 (1.12-2.59) | ||||||
For all patients, n = 1328; for patients 60 years old or younger, n = 737.
Not significant (NS) were the following: platelets, LDH (log), sex, MLL-PTD, FLT3-TKD, BM blasts.
GPT/L indicates gigaparticles per liter; —, not applicable.
Cytogenetics were as defined by the Medical Research Council (MRC) study group; if more than two groups were built, a reference group was used.
For cytogenetics, the intermediate group was was set as the reference group; for WBC counts, lowest WBC count (9.2 or fewer GPT/L) was set as the reference group; and for de novo AML versus sAML NPM1-FLT3 group, NPM1-wt/FLT3-ITDneg was set as the reference group.